On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46. The U.S. drugmaker reported sales of $13.28 billion, up 2% ...

Pfizer has underperformed the market in each of the past three years. The stock is doing well of late as investors have been turning to safer investments amid uncertainty. Pfizer has been struggling ...

Pfizer (NYSE: PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That ...

Pfizer (NYSE: PFE) is scheduled to report its Q3 2024 results on Tuesday, October 29. We expect the company to post revenue of $15.1 billion and earnings of $0.63 on a per share and adjusted basis, ...

Pfizer is a drug company. That's a very complex line of work, with the company searching for and developing new drugs. It then has to test the drugs and get them approved by regulators. There are huge ...

Pfizer (NYSE: PFE) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over that stretch, while the S&P 500 has climbed by 68%. Investors have lost ...